Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
Clinical Cancer Research, ISSN: 1557-3265, Vol: 21, Issue: 14, Page: 3196-3203
2015
- 447Citations
- 314Captures
- 3Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations447
- Citation Indexes441
- 441
- CrossRef306
- Clinical Citations3
- PubMed Guidelines3
- Policy Citations3
- Policy Citation3
- Captures314
- Readers314
- 314
- Mentions3
- Blog Mentions1
- Blog1
- News Mentions1
- News1
- References1
- Wikipedia1
Most Recent News
Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma
STUDY INFORMATION OFFICIAL TITLE: Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma CURRENT STATUS: Recruiting: 2 Years STUDY TYPE:
Article Description
Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and blood samples from the FASTACT-2 study. Experimental Design: Patients were randomized to receive six cycles of gemcitabine/platinum plus sequential erlotinib or placebo. EGFR mutation testing was performed using the cobas tissue test and the cobas blood test (in development). Blood samples at baseline, cycle 3, and progression were assessed for blood test detection rate, sensitivity, and specificity; concordance with matched tumor analysis (n = 238), and correlation with progressionfree survival (PFS) and overall survival (OS). Results: Concordance between tissue and blood tests was 88%, with blood test sensitivity of75%and a specificity of 96%. Median PFS was 13.1 versus 6.0 months for erlotinib and placebo, respectively, for those with baseline EGFR mut+ cfDNA [HR, 0.22; 95% confidence intervals (CI), 0.14-0.33, P < 0.0001] and 6.2 versus 6.1 months, respectively, for the EGFR mut cfDNA subgroup (HR, 0.83;95%CI, 0.65-1.04, P=0.1076). For patients with EGFR mut+ cfDNA at baseline, median PFS was 7.2 versus 12.0 months for cycle 3 EGFR mut+ cfDNA versus cycle 3 EGFR mut patients, respectively (HR, 0.32; 95% CI, 0.21-0.48, P < 0.0001); median OS by cycle 3 status was 18.2 and 31.9 months, respectively (HR, 0.51; 95% CI, 0.31-0.84, P = 0.0066). Conclusions: Blood-based EGFR mutation analysis is relatively sensitive and highly specific. Dynamic changes in cfDNA EGFR mutation status relative to baseline may predict clinical outcomes.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84938399710&origin=inward; http://dx.doi.org/10.1158/1078-0432.ccr-14-2594; http://www.ncbi.nlm.nih.gov/pubmed/25829397; https://aacrjournals.org/clincancerres/article/21/14/3196/125221/Detection-and-Dynamic-Changes-of-EGFR-Mutations; http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-14-2594; https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-14-2594; https://dx.doi.org/10.1158/1078-0432.ccr-14-2594; https://clincancerres.aacrjournals.org/content/21/14/3196
American Association for Cancer Research (AACR)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know